CAI
Clinical Asset Index
by VOS Supply Group
Drugs · acquisition-cost intelligence

Aleve-D Sinus and Cold

Naproxen sodium and Pseudoephedrine Hydrochloride· ingredient naproxenAntiinflammatory preparations, non-steroids for topical use· NAPROXEN SODIUM 220 mg/1; PSEUDOEPHEDRINE HYDROCHLORIDE 120 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.24430
NADAC — pharmacy acquisition cost, not a retail/cash price

Acquisition-cost history

Weekly NADAC per EA — the trend nobody else shows. 5 weeks.

2025-08-202026-05-20

Same-ingredient options by acquisition cost

Other naproxen products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.

ProductNADAC / EAvs this
Naproxen$0.05893−$0.18540
Naprotin$0.06254−$0.18180
24/7 Life by 7-Eleven Naproxen Sodium$0.06496−$0.17930
Aleve$0.14651−$0.09780
Naproxen Oral Suspension$0.17537−$0.06890
Naproxen sodium$0.22001−$0.02430
Naproxen$1.91+$1.66
Naprelan$9.28+$9.03

Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.